Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population

Clinica Chimica Acta

Volumn 407, Issue 1-2, 2009, Pages 30-35

  Ma, Jing Jing ^a   Liu, Cun Gang ^a   Li, Jin Heng ^a   Cao, Xiao Mei ^a   Sun, Sheng Li ^a   Yao, Xuan ^a  

^a JINLING HOSPITAL   (China)

Author keywords

Chinese subjects; Genetic polymorphism; N Acetyltransferase 2; Pharmacogenetics; Sulfasalazine

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; N ACETYLSULFAPYRIDINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENTERIC COATED TABLET; FEASIBILITY STUDY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; TABLET FORMULATION; WILD TYPE;

ADMINISTRATION, ORAL; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CALIBRATION; CHINA; FEASIBILITY STUDIES; HUMANS; MALE; POLYMORPHISM, GENETIC; QUALITY CONTROL; SULFAPYRIDINE; SULFASALAZINE; YOUNG ADULT;

EID: 67651091328     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.06.025     Document Type: Article

References (49)

1. Plosker G.L., and Croom K.F. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65 (2005) 1825-1849
2. Peppercorn M.A. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann Intern Med 101 (1984) 377-386
3. Nissilä M., Lehtinen K., Leirisalo-Repo M., Luukkainen R., Mutru O., and Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 31 (1988) 1111-1116
4. Ferraz M.B., Tugwell P., Goldsmith C.H., and Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17 (1990) 1482-1486
5. Duparc A., Staumont-Sallé D., Broly F., Piette F., and Delaporte E. Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal. Presse Med 35 (2006) 1138-1142
6. Olmez D., Babayigit A., Uzuner N., et al. Efficacy of sulphasalazine on lung histopathology in a murine model of chronic asthma. Exp Lung Res 34 (2008) 501-511
7. Das K.M., and Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1 (1976) 406-425
8. Fischer C., Maier K., Stumpf E., von Gaisberg U., and Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharamcol 25 (1983) 511-515
9. Bird H.A. Sulfasalazine, sulphapyridine or 5-aminosalicylic acid-which is the active moiety in rheumatoid arthritis?. Br J Rheumatol 34 suppl.2 (1995) 16-19
10. Das K.M., Eastwood M.A., McManus J.P., and Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut 14 (1973) 631-641
11. Ricart E., Taylor W.R., Loftus E.V., et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. Am J Gastroenterol 97 (2002) 1763-1768
12. Meyer U.A., and Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37 (1997) 269-296
13. Meisel P. Arylamine N-acetyltransferase and drug response. Pharmacogenomics 3 (2002) 349-366
14. Lee C.N., Yu M.C., Bai K.J., et al. NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. Lung Cancer 64 (2009) 9-12
15. Gunnarsson I., Kanerud L., Pettersson E., Lundberg I., Lindblad S., and Ringertz B. Predisposing factors in Sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36 (1997) 1089-1094
16. Chen B., Li J.H., Xu Y.M., Wang J., and Cao X.M. The influence of NAT2 on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta 365 (2006) 104-108
17. Zang Y., Zhao S., Doll M.A., Christopher States J., and Hein D.W. Functional characterization of the A411T(L137F) and G364A(D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet Genomics 17 (2007) 37-45
18. http://louisville.edu/medschool/pharmacology/NAT2.html.
19. Lu J.F., Cao X.M., Liu Z.H., et al. Genetic analysis of N-acetyltransferase polymorphism in a Chinese population. Zhongguo Yao Li Xue Bao 19 (1998) 347-351
20. Xu S.Y., and Wei W. Clinical pharmacology. third ed. (2004), People's medical publishing house, Beijing
21. Das K.M., Eastwood M.A., McManus J.P., and Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289 (1973) 491-495
22. Schröder H., and Evans D.A.P. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13 (1972) 278-284
23. Soejima M., Kawaguchi Y., Hara M., and Kamatani N. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis. J Rheumatol 35 (2008) 724
24. Sabbagh N., Delaporte E., Marez D., Lo-Guidice J.M., Piette F., and Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 7 (1997) 131-135
25. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol 74 (2008) 611-613
26. Kim J.Y., Cho H.J., Sir J.J., et al. Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. Cardiovasc Res 82 (2009) 550-560
27. - cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol 64 (2009) 463-472
28. Kawamoto K., Lobach D.F., and Willard H.F. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med Inform Decis Mak 9 (2009) 17
29. Xiao P.F., Cheng L., Wan Y., et al. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 27 (2006) 3904-3915
30. Li J.H., Liu C.G., Yao X., et al. Quantification of sulfasalazine and its metabolites in human plasma by HPLC. J Med Postgrad 21 (2008) 682-684
31. Wu G.H., Meng Y., Zhu X.H., and Huang C. Pharmacokinetics and tissue distribution of enrofloxacin and its metabolite ciprofloxacin in the Chinese mitten-handed crab, Eriocheir sinensis. Anal Biochem 358 (2006) 25-30
32. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China, supplement 2000 ed (2002), Chemical Industry Press, Beijing
33. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 (1999) 487-491
34. Jain K.K. Role of nanobiotechnology in the development of personalized medicine. Nanomedicine 4 (2009) 249-252
35. Chen M., Xia B., Chen B.X., et al. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulfasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 21 (2007) 155-158
36. Cascorbi I., Drakoulis N., Brockmoller J., Maurer A., Sperling K., and Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57 (1995) 581-592
37. Kumagai S., Komada F., Kita T., et al. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 21 (2004) 324-329
38. Kita T., Sakaeda T., Adachi S., et al. N-acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. Biol Pharm Bull 24 (2001) 1176-1180
39. Yamasaki K., Ieiri I., Kusuhara H., et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphism in humans. Clin Pharmacol Ther 84 (2008) 95-103
40. Azad Khan A.K., Johnston H.H., and Truelove S.C. Proceedings: bacterial breakdown of sulphasalazine (salazopyrin). Gut 16 (1975) 832
41. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10 4 (1985) 285-302
42. Tanaka E., Taniguchi A., Urano W., et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29 (2002) 2492-2499
43. Taniguchi A., Urano W., Tanaka E., et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 17 (2007) 383-390
44. Rahav G., Zylber-Katz E., Rachmilewitz D., and Levy M. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Isr J Med Sci 26 (1990) 31-34
45. Azad Khan A.K., Howes D.T., Piris J., and Truelove S.C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 21 3 (1980) 232-240
46. Pullar T. Adverse effects of sulphasalazine. Adverse Drug React Toxicol Rev 11 (1992) 93-109
47. Taffet S.L., and Das K.M. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 28 9 (1983) 833-842
48. Astbury C., Taggart A.J., Juby L., Zebouni L., and Bird H.A. Comparison of the single dose pharmacokinetics sulphasalazine in rheumatoid arthritis and inflammatory bowel disease. Ann Rheum Dis 49 (1990) 587-590
49. Knowles S.R., Uetrecht J., and Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356 (2000) 1587-1591